Anti-inflammatory oral drug colchicine improved COVID-19 outcomes for patients with relatively mild cases, according to certain topline results from the COLCORONA trial announced in a brief press ...

Colchicine, long used to reduce inflammation in gout flares, might also protect patients with gout from cardiovascular (CV) events, according to a study published online November 18, 2015, in the ...

Please provide your email address to receive an email when new articles are posted on . Patients taking colchicine had a weighted hazard ratio of 0.82 (95% CI, 0.69-0.94) for cardiovascular events.

Please provide your email address to receive an email when new articles are posted on . More than 25% of patients with gout who use colchicine prophylaxis were on potentially interacting medications.

Patients with gout are commonly prescribed colchicine prophylaxis, despite already taking medications that could potentially interact. Patients with gout are commonly prescribed colchicine prophylaxis ...

In patients with gout starting allopurinol as a long-term urate-lowering therapy, the prophylactic use of nonsteroidal anti-inflammatory drugs (NSAIDs) was associated with a higher risk for major ...

A press release from a Canadian research group raised hopes that treating people recently diagnosed with Covid-19 with colchicine, a drug commonly used to treat gout, could reduce the risk they will ...

Colcrys, a new colchicine formulation, has received marketing clearance for the prevention of gout flares. The FDA first approved the oral medication in July for the treatment of acute gout flares ...